文献速递免疫规划

九价人乳头瘤病毒疫苗接种5年后的抗体持久性与免疫记忆证据

Antibody persistence and evidence of immune memory at 5years following administration of the 9-valent HPV vaccine.
PubMed 文献 · Vaccine · 2017-08-05

该研究对完成3剂九价HPV疫苗基础免疫的受试者(N=150)在60个月时接种第4剂,评估抗体持久性与免疫记忆。结果显示基础免疫后抗体阳转率维持77.5%–100%,第4剂后1周和1个月阳转率分别>99%和100%,几何平均滴度较基础免疫后1个月分别升高1.25–4.10倍和1.65–4.88倍,第4剂总体耐受良好。

要点

  • 3剂九价HPV疫苗后60个月抗体阳转率维持77.5%–100%。
  • 第4剂后1周和1个月阳转率分别>99%和100%。
  • 第4剂后几何平均滴度较基础免疫后1个月升高1.25–4.10倍(1周)和1.65–4.88倍(1个月)。

核心结论

  • 3剂九价HPV疫苗诱导的抗体应答持续至接种后5年,第4剂对全部9种疫苗型别产生强回忆应答,提示疫苗效力可能持久。

研究设计与样本

  • 关键效力研究的延伸研究,纳入基础研究第1天、第2个月、第6个月接种3剂九价HPV疫苗的受试者亚组(N=150),在第60个月接种第4剂。
  • 采用竞争性Luminex免疫分析法检测第4剂前及第4剂后7天和28天的血清HPV抗体水平,并采用疫苗接种报告卡评估不良事件。

主要发现

  • 基础研究3剂系列后诱导的HPV抗体持续至第60个月,阳转率范围为77.5%至100%。
  • 第4剂后1周和1个月几何平均滴度分别较3剂基础系列完成后1个月观察到的水平升高1.25–4.10倍和1.65–4.88倍。
  • 第4剂后1周和1个月阳转率分别>99%和100%。
  • 第4剂九价HPV疫苗总体耐受良好。

局限性

  • 保护持续时间仍有待确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The 9-valent HPV (9vHPV) vaccine was developed to prevent infection and disease related to 9 HPV types (HPV6/11/16/18/31/33/45/52/58) which cause approximately 90% of cervical cancers, HPV-related vulvar, vaginal and anal cancers, and genital warts worldwide. In a pivotal efficacy study, the 9vHPV vaccine prevented infection and disease due to the 9 vaccine types. Duration of protection remains to be determined. Vaccines that induce long-term protection are generally characterized by the generation of immune memory. The purpose of this report is to assess the persistence of HPV antibody response and existence of immune memory at 5years post-vaccination. METHODS: A subset of subjects (N=150) who received 3 doses of 9vHPV vaccine at day 1, month 2 and month 6 in the pivotal efficacy study continued in a study extension and received a fourth dose of 9vHPV vaccine at month 60. Serum HPV antibody levels were measured pre-dose 4 and at 7 and 28days post-dose 4 by competitive Luminex immunoassay. Adverse events were assessed using a vaccination report card. RESULTS: HPV antibodies induced following the 3-dose series of 9vHPV vaccine in the base study persisted through month 60 with seropositivity rates ranging from 77.5% to 100%. Geometric mean titers at 1week and 1month post-dose 4 were 1.25-4.10 and 1.65-4.88-fold higher, respectively, than levels observed 1month following the completion of the three-dose primary series. Seropositivity rates were >99% and 100% at 1week and 1month post-dose 4, respectively. The fourth dose of 9vHPV vaccine was generally well tolerated. CONCLUSIONS: A three-dose regimen of the 9vHPV vaccine induced persistent HPV antibody response through 5years post-vaccination. Administration of a fourth dose resulted in a strong anamnestic response to all 9 vaccine types. These findings suggest that the efficacy of the 9vHPV vaccine will be long lasting. Clinical Trials.gov Identifier:NCT00543543.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Guevara A, Cabello R, Woelber L, et al. Antibody persistence and evidence of immune memory at 5years following administration of the 9-valent HPV vaccine. Vaccine. 2017. PMID: 28789851. doi:10.1016/j.vaccine.2017.07.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。